润本股份: 股东减持股份结果公告

Summary of Key Points Core Viewpoint - JNRY VIII HK Holdings Limited, a major shareholder of Runben Biotechnology Co., Ltd., has executed a share reduction plan, selling a total of 3,608,400 shares, which is 0.89% of the company's total share capital, as part of its investment strategy [1][2]. Group 1: Shareholder Information - JNRY VIII held 22,252,566 shares before the reduction, representing 5.50% of the total share capital [1]. - The shares were acquired prior to the company's IPO and became tradable on October 17, 2024 [1]. Group 2: Reduction Plan Implementation - The reduction plan allowed for a maximum sale of 12,137,799 shares (3.00% of total shares), with specific limits of 4,045,933 shares (1.00%) through open market transactions and 8,091,866 shares (2.00%) through block trades [1]. - The actual reduction was completed within the designated timeframe, with the shares sold at prices ranging from 30.01 to 36.20 yuan per share, totaling approximately 123.24 million yuan [2][3]. Group 3: Current Shareholding Status - After the reduction, JNRY VIII currently holds 18,644,166 shares, which is 4.61% of the total share capital [2]. - The reduction plan was executed as planned, with no early termination of the plan [3].